Terms: = Gastric cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
731 results:
1. Clinical biomarkers for thyroid immune-related adverse events in patients with stage III and IV gastrointestinal tumors.
Xing N; Liu J; Hou L; Zhao Y; Ma H; Wang F; Guo Z
Front Immunol; 2024; 15():1381061. PubMed ID: 38774877
[TBL] [Abstract] [Full Text] [Related]
2. An On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reflects Short-Term Efficacy of pd-1 Blockade Immunochemotherapy in Patients with Advanced gastric cancer.
Liu J; Mao Y; Mao C; Wang D; Dong L; Zhu W
J Immunol Res; 2024; 2024():3604935. PubMed ID: 38774604
[TBL] [Abstract] [Full Text] [Related]
3. State-of-the-Art Advancements in Gastroesophageal cancer Treatment: Harnessing Biomarkers for Precision Care.
Balmaceda NB; Petrillo A; Krishnan M; Zhao JJ; Kim S; Klute KA; Sundar R
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431060. PubMed ID: 38771996
[TBL] [Abstract] [Full Text] [Related]
4. The optimal threshold of PD-L1 combined positive score to predict the benefit of pd-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.
Li JB; Lai MY; Lin ZC; Guan WL; Sun YT; Yang J; Wang WX; Yang ZR; Qiu MZ
Cancer Immunol Immunother; 2024 May; 73(7):132. PubMed ID: 38753055
[TBL] [Abstract] [Full Text] [Related]
5. Deep learning based digital pathology for predicting treatment response to first-line pd-1 blockade in advanced gastric cancer.
Liu Y; Chen W; Ruan R; Zhang Z; Wang Z; Guan T; Lin Q; Tang W; Deng J; Wang Z; Li G
J Transl Med; 2024 May; 22(1):438. PubMed ID: 38720336
[TBL] [Abstract] [Full Text] [Related]
6. New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model.
Yu D; Yang J; Wang B; Li Z; Wang K; Li J; Zhu C
Cancer Immunol Immunother; 2024 May; 73(6):112. PubMed ID: 38693422
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
[TBL] [Abstract] [Full Text] [Related]
8. Creatinine-to-cystatin C ratio and body composition predict response to pd-1 inhibitors-based combination treatment in metastatic gastric cancer.
Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
[TBL] [Abstract] [Full Text] [Related]
9. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
10. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
Deng Z; Feng Q; Zhao D; Huang Z
Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
[TBL] [Abstract] [Full Text] [Related]
11. Combination of IFN-gamma with STING agonist and pd-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer.
Hosseinzadeh S; Imani M; Pourfarzi F; Jafari N; AbedianKenari S; Safarzadeh E
Med Oncol; 2024 Apr; 41(5):110. PubMed ID: 38592576
[TBL] [Abstract] [Full Text] [Related]
12. HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer.
Suo D; Gao X; Chen Q; Zeng T; Zhan J; Li G; Zheng Y; Zhu S; Yun J; Guan XY; Li Y
J Exp Clin Cancer Res; 2024 Apr; 43(1):106. PubMed ID: 38589927
[TBL] [Abstract] [Full Text] [Related]
13. Associations of pd-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
14. First-line camrelizumab (a pd-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X; Xu H; Chen X; Xu T; Tian Y; Wang D; Guo F; Wang K; Jin G; Li X; Wang R; Li F; Ding Y; Tang J; Fang Y; Zhao J; Liu L; Ma L; Meng L; Hou Z; Zheng R; Liu Y; Guan N; Zhang B; Tong S; Chen S; Li X; Shu Y
Signal Transduct Target Ther; 2024 Mar; 9(1):73. PubMed ID: 38528050
[TBL] [Abstract] [Full Text] [Related]
15. Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies.
Peng H; Wu X; Zhang C; Liang Y; Cheng S; Zhang H; Shen L; Chen Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):153. PubMed ID: 38519621
[TBL] [Abstract] [Full Text] [Related]
16.
Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
[TBL] [Abstract] [Full Text] [Related]
17. Serum iron element: A novel biomarker for predicting pd-1 immunotherapy efficacy.
Luan F; Wang J; Liu L; Liu B; Li F; Zhao J; Lai J; Jiang F; Xu W; Zhang Z; Ran P; Shu Y; Yang Z; Fu G
Int Immunopharmacol; 2024 Apr; 131():111823. PubMed ID: 38508094
[TBL] [Abstract] [Full Text] [Related]
18. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
Deng G; Zhu D; Du Z; Xue Y; Song H; Li Y
Cancer Med; 2024 Mar; 13(6):e7110. PubMed ID: 38506237
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
Kelly RJ; Landon BV; Zaidi AH; Singh D; Canzoniero JV; Balan A; Hales RK; Voong KR; Battafarano RJ; Jobe BA; Yang SC; Broderick S; Ha J; Marrone KA; Pereira G; Rao N; Borole A; Karaindrou K; Belcaid Z; White JR; Ke S; Amjad AI; Weksler B; Shin EJ; Thompson E; Smith KN; Pardoll DM; Hu C; Feliciano JL; Anagnostou V; Lam VK
Nat Med; 2024 Apr; 30(4):1023-1034. PubMed ID: 38504015
[TBL] [Abstract] [Full Text] [Related]
20. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract] [Full Text] [Related]
[Next]
